Andrew J. Idzior

FDA investigator · also recorded as Eas Andrew J. Idzior

Appears on 6 documents from 2013 to 2018, most often at sites in India. Most often cites control of microbiological contamination (21 CFR 211.113).

6
Documents on file
5.5
Observations per 483
2013
First seen
2018
Most recent

What they cite most

From 32 observations

Activity by year

2013: 1, 2014: 1, 2015: 1, 2017: 1, 2018: 2

Where

India 2 · Michigan 2 · Washington 1 · Wisconsin 1

Is Andrew J. Idzior coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

6 documents, newest first
FirmOpen
483 Strides Pharma Science Limited 36/7, Suragajakkanahalli, Indlawadi Cross, Anekal TalukAug 24, 2018 · Bengaluru, India
483 Medline Industries, LP (f/k/a Medline Industries, Inc.)May 25, 2018 · Hartland, Wisconsin
483 Lupin Limited 15-B, Phase 1A, Verna Industrial AreaApr 7, 2017 · Verna, India
483 Pharmacia & Upjohn Company LLCJul 9, 2015 · Kalamazoo, Michigan
483 Jubilant HollisterStier, LLCApr 15, 2014 · Spokane, Washington
483 Caraco Pharmaceutical Laboratories, Ltd.Jan 11, 2013 · Detroit, Michigan

About this profile

What does Andrew J. Idzior inspect?

Andrew J. Idzior appears on 6 documents on file covering 6 sites, most often in India.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.192 and 21 CFR 211.194(a)(4).

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Andrew J. Idzior is dated Aug 24, 2018.